FY2028 Earnings Estimate for PRQR Issued By HC Wainwright

Key Points

• HC Wainwright lowered its FY2028 EPS estimate for ProQR Therapeutics to a loss of $0.37 per share from $0.27 previously, while maintaining a Buy rating and an $8.00 price target.
• Analyst sentiment remains broadly positive: six analysts rate the stock Buy, with an average rating of “Moderate Buy” and an average price target of $7.60.
• ProQR reported a quarterly loss of $0.09 per share, beating the $0.13-loss consensus, while revenue of $10 million exceeded expectations of $4.56 million. Insiders also purchased 450,000 shares worth $757,500 over the past 90 days.

ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Stock analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a research report issued to clients and investors on Thursday, October 1st. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings of ($0.37) per share for the year, down from their previous forecast of ($0.27). HC Wainwright has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for ProQR Therapeutics' FY2029 earnings at ($0.32) EPS and FY2030 earnings at ($0.18) EPS.

Several other analysts have also recently weighed in on the stock. Citigroup reiterated a "market outperform" rating on shares of ProQR Therapeutics in a research note on Thursday. Bank of America assumed coverage on shares of ProQR Therapeutics in a research report on Thursday, August 20th. They set a "buy" rating and a $8.00 target price on the stock. Chardan Capital reiterated a "buy" rating and issued a $3.00 price target on shares of ProQR Therapeutics in a research report on Thursday. Weiss Ratings upgraded shares of ProQR Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 14th. Finally, JonesTrading cut their price target on ProQR Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research note on Friday, June 26th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $7.60.

ProQR Therapeutics Stock Performance

PRQR stock opened at $1.64 on Monday. The company's 50-day simple moving average is $1.94 and its 200 day simple moving average is $1.76. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $3.10. The company has a market capitalization of $172.26 million, a PE ratio of -3.55 and a beta of 0.20.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%.The firm had revenue of $10.00 million for the quarter, compared to analysts' expectations of $4.56 million.

Institutional Trading of ProQR Therapeutics

Several large investors have recently made changes to their positions in the company. Walleye Capital LLC increased its stake in ProQR Therapeutics by 2.7% in the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company's stock valued at $984,000 after acquiring an additional 15,744 shares during the last quarter. Bank of America Corp DE raised its position in ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company's stock valued at $300,000 after purchasing an additional 11,186 shares in the last quarter. RFG Advisory LLC lifted its stake in ProQR Therapeutics by 236.8% during the second quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company's stock worth $119,000 after purchasing an additional 45,000 shares during the last quarter. Finally, Axiom Investment Management LLC bought a new stake in ProQR Therapeutics during the first quarter worth $53,000. Institutional investors and hedge funds own 32.65% of the company's stock.

Insider Activity

In other news, Director Bart Filius acquired 150,000 shares of ProQR Therapeutics stock in a transaction on Friday, July 17th. The shares were purchased at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the purchase, the director directly owned 300,000 shares of the company's stock, valued at approximately $516,000. This represents a 100.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Daniel de Boer acquired 150,000 shares of ProQR Therapeutics stock in a transaction on Thursday, July 9th. The shares were purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the completion of the purchase, the chief executive officer directly owned 300,000 shares of the company's stock, valued at approximately $522,000. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 450,000 shares of company stock valued at $757,500 in the last ninety days. 8.40% of the stock is currently owned by company insiders.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company's research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR's technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.